News | March 10, 2026
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
The first of four planned modules at the new plant is expected to come online by summer 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
